NCT01979523 2026-03-19
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
88 trialsNCT01587352 2026-03-18
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05907954 2026-03-16
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
Phase 2 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT06414590 2026-03-03
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT03417739 2026-02-25
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT04645680 2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06717126 2026-01-16
OCULE-01
iOnctura
Phase 2 Active not recruiting
NCT05524935 2026-01-08
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07276386 2025-12-11
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT01473004 2025-11-14
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Thomas Jefferson University
Phase 2 Completed
NCT05170334 2025-10-01
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT04728633 2025-08-06
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT05315258 2025-07-17
TebeMRD
University of Oxford
Phase 2 Active not recruiting
NCT04720417 2025-07-15
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT03467516 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT05187884 2025-06-24
NADOM
St Vincent's Hospital, Sydney
Phase 2 Active not recruiting
NCT06932757 2025-06-03
Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT05542342 2025-05-14
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03472586 2025-04-24
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Thomas Jefferson University
Phase 2 Completed
NCT01355120 2025-04-09
DeCOG
University Hospital, Essen
Phase 2 Completed
NCT04417530 2025-03-03
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Aura Biosciences
Phase 2 Completed
NCT02936388 2025-01-24
SirTac
Charite University, Berlin, Germany
Phase 2 Completed
NCT01585194 2024-07-09
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00020475 2024-03-04
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02697630 2023-12-08
PEMDAC
Vastra Gotaland Region
Phase 2 Completed
NCT02223819 2023-12-06
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
Phase 2 Completed
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Recruiting
NCT01835145 2022-08-04
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084656 2022-04-14
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT02626962 2022-03-22
GEM1402
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT02129075 2021-11-16
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02363283 2020-08-21
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT01413191 2020-02-19
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed